Avastin (bevacizumab) / Roche |
NCT01441388: A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. |
|
|
| Withdrawn | 1b | 0 | US | Crizotinib plus VEGF inhibitor combinations, Crizotinib plus axitinib, Crizotinib plus sunitinib, Crizotinib plus bevacizumab, Crizotinib plus sorafenib | Pfizer | Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular | 11/13 | 11/13 | | |
| Completed | 1b | 22 | US | CRLX101 (Cerulean), Bevacizumab | Abramson Cancer Center of the University of Pennsylvania | Renal Cell Carcinoma | 07/17 | 07/18 | | |
|
|
|
|
|
|
NCT00421512: A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients |
|
|
| Completed | 1 | 28 | US | Bevacizumab and Sunitinib | Memorial Sloan Kettering Cancer Center | Metastatic Renal Cell Carcinoma, Kidney Cancer | 05/08 | 05/08 | | |
NCT00683241: A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer |
|
|
| Completed | 1 | 36 | US | DCVac-L | Abramson Cancer Center of the University of Pennsylvania, Northwest Biotherapeutics, University of California, San Francisco | Ovarian Cancer, Peritoneal Cancer | 12/09 | 12/09 | | |
NCT01202890: Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer |
|
|
| Terminated | 1 | 1 | US | Lenalidomide, Liposomal Doxorubicin, Bevacizumab, Revlimid, Doxil, Avastin | New Mexico Cancer Care Alliance, Celgene Corporation | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | 05/11 | 05/12 | | |
NCT01219777: Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian |
|
|
| Completed | 1 | 9 | US | carboplatin, Paraplatin®, CBDCA, Bevacizumab, Avastin, Paclitaxel, Taxol, Abraxane | Ritu Salani, Genentech, Inc. | Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 05/12 | 05/15 | | |
PARASOL, NCT01202032: Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors |
|
|
| Completed | 1 | 36 | Europe | Association of Bevacizumab (BVC)+ Pazopanib (PZP) | Centre Leon Berard | Metastatic Renal Cell Carcinoma, Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed | 01/13 | 03/13 | | |
|
|
NCT00992121: An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma |
|
|
| Completed | 1 | 11 | Europe | Bevacizumab, Pazopanib 2 week, Pazopanib 3 week | GlaxoSmithKline | Carcinoma, Renal Cell | 11/13 | 11/13 | | |
NCT01243359: Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies |
|
|
| Completed | 1 | 6 | US | sunitinib malate, SU11248, sunitinib, Sutent, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, pharmacological study, pharmacological studies, laboratory biomarker analysis, fluorine F 18 fluorothymidine, 18F-FLT, 3'-deoxy-3'-[18F]fluorothymidine, fluorothymidine F-18, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, computed tomography, tomography, computed | National Cancer Institute (NCI) | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 02/14 | | | |
|
CHIPASTIN, NCT02217956: Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma |
|
|
| Completed | 1 | 30 | Europe | Cisplatin, Bevacizumab | Gustave Roussy, Cancer Campus, Grand Paris | Ovarian Adenocarcinoma, Fallopian Tube Adenocarcinoma, Primary Peritoneal Carcinoma | 06/15 | 06/15 | | |
NCT01248949: A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors |
|
|
| Completed | 1 | 162 | US | MEDI3617, Bevacizumab, Paclitaxel, Carboplatin | MedImmune LLC | Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors | 07/15 | 10/15 | | |
|
NCT01183663: Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) |
|
|
| Completed | 1 | 180 | US | Lenalidomide, CC-5013, Revlimid, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAB-VEGF, Sorafenib, Nexavar, BAY 43-90006, Temsirolimus, CC-779, Torisel, Oxaliplatin, Eloxatin, Leucovorin, Citrovorum, Wellcovorin, 5-fluorouracil, 5-FU, Adrucil, Efudex | M.D. Anderson Cancer Center, Celgene | Advanced Cancers | 05/16 | 05/16 | | |
|
|
|
NCT01283048: Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma |
|
|
| Completed | 1 | 32 | US | BKM-120 Bevacizumab, Avastin | Toni Choueiri, MD, Beth Israel Deaconess Medical Center | Renal Cell Carcinoma | 09/16 | 09/16 | | |
|
NCT01995188: A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer |
|
|
| Completed | 1 | 41 | US | Bevacizumab, Avastin, Carboplatin, DNIB0600A | Genentech, Inc. | Non-Squamous Non-Small Cell Lung Cancer | 11/16 | 11/16 | | |
NCT02835833: Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors |
|
|
| Completed | 1 | 21 | US | Nintedanib, BIBF1120, Bevacizumab, Avastin | University of Alabama at Birmingham, Boehringer Ingelheim | Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma | 04/18 | 06/18 | | |
| Completed | 1 | 67 | US | OCDC | Abramson Cancer Center of the University of Pennsylvania | Chemotherapy, Tumor, Ovarian Cancer | 05/18 | 05/18 | | |